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Abstract
Background: The fibrinogen receptor is an integrin on the platelet surface and is shaped from two types of
glycoprotein (GP) subunits, GPIIb and GPIIIa. Membrane glycoprotein IIb/IIIa plays an important role in platelet
function. The gene encoding the glycoprotein IIIa shows a common polymorphism, PLA2 that increases the
binding of the receptor to fibrinogen and enhances the platelet aggregation. The clinical impact of PLA2
polymorphism has been studied in some diseases, but the definition of its exact role on venous thromboembolism
complications has been challenging. The present systematic review aimed to clarify the association of PLA2
polymorphism and venous thromboembolism.
Main text: In this study, Electronic databases including PubMed, Embase, Scopus, Web of Science, and Cochrane
Library were searched. All the assessed studies focused on the relationship between PLA2 polymorphism and
venous thromboembolism. Five studies were eligible for systematic review. One study revealed a significant
correlation between PLA2 polymorphism and venous thromboembolism. PLA2 polymorphism was associated with
deep vein thrombosis in one study and pulmonary thromboembolism in another one.
Conclusion: The published data supported the hypothesis that having the PLA2 polymorphism of GPIIIa may be a
risk factor for venous thromboembolism, but the association cannot be concluded; it needs more clinical
investigation.
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Background
The platelet fibrinogen receptor is essential for prelimin-
ary hemostasis, as it regulates platelet aggregation and
binds to a combination of fibrinogen, von Willebrand
factor (vWF), and fibronectin for the formation of a
stable thrombus following vascular injury [1–3].
The mature fibrinogen receptor is an integrin on the
platelet surface [4] and is formed from two types of
glycoprotein (GP) subunits, GPIIb and GPIIIa [5]. The
GP IIIa subunit is a great polymorphic protein with
platelet antigen 1 (PLA1) and 2 (PLA2) as the utmost
stable allelic variants [6]. The PLA2 polymorphism of
GP IIIa results from the substitution of leucine by pro-
line at position 33 [7].
Previous studies demonstrated that the PLA2 isoform
increases the binding of the GP IIb/IIIa receptor to fi-
brinogen and enhances the platelet aggregation, thus it is
a possible factor for thrombotic tendency with other
prevalent recognized inherited thrombophilic factors such
as factor V Leiden (FVL), mutation G20210A in pro-
thrombin gene, and factor XIII polymorphism [8–11].
The clinical impact of PLA2 polymorphism (formed
from GP IIIa) has been associated with an increased risk
of several diseases where thrombus formation is a crucial
pathogenic factor for their development such as
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myocardial infarction and stroke, and was suggested as a
risk factor for venous thromboembolism (VTE) [2, 12–
15]. VTE, including pulmonary embolism (PE) and deep
vein thrombosis (DVT), is a major public health problem
[16], mostly for hospitalized patients [17] and is among
the utmost ordinary preventable reasons of hospital
death [18]. VTE appears to be triggered by acquired and
hereditary risk factors including mutations in genes en-
coding hemostatic proteins such as coagulation factors,
coagulations inhibitors, and platelet glycoproteins.
Some studies investigated the role of the PLA2 polymorph-
ism in DVT, PE, or VTE, but this is still controversial.
To the best of our knowledge, the association between
PLA2 polymorphism and VTE has not been systematically
assessed. Therefore, this systematic review aimed to evalu-
ate the prognostic significance of PLA2 polymorphism in
DVT, PE, and VTE patients to explore the relationship be-
tween this polymorphism and venous thrombotic events.
Main text
Search strategy
Search strategy and selection of articles for this system-
atic review were performed in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement (Fig. 1).
We searched the different databases including Pub
Med, Scopus, Web of Science, Embase, and Cochrane li-
brary databases up to January 2018. Electronic searches
were performed combining some keywords that were
planned to proper match to MeSH terms.
“PLA2 polymorphism” and “Deep vein thrombosis,”
“PLA2 polymorphism” and “Pulmonary embolism,”
“PLA2 polymorphism” and “Venous thromboembolism”
or “VTE,” “PLA2 polymorphism” and “Deep vein throm-
bosis” or “DVT,” or “Pulmonary Embolism” or “Venous
thromboembolism.”
We also manually searched the reference lists of pri-
mary studies and reviews, in order to find the studies
which cannot be found via an electronic search.
Selection criteria
Duplicates were initially removed from the search result.
The remaining articles were then screened by scanning
titles and abstracts for the inclusion criteria: articles
studying the relationship between having the PLA2 poly-
morphism and risk of DVT, PE, and VTE (at least one
of these); studies calculated odds ratio; and published ar-
ticles in English language.
The exclusion criteria of this review study were as fol-
lows: not original articles including commentaries, re-
view articles, case reports, and letters; papers in any
language except English; articles with less than ten pa-
tients; articles that do not contain full text, including
articles presented at congresses and conferences and
symposiums.
Article selection was conducted by authors independ-
ently. Any disagreement among reviewers was resolved
by discussion and reached consensus finally.
Data extraction and quality assessment
One of the reviewers thoroughly investigated the article
titles and abstracts to determine the competency of se-
lected articles.
The following data were obtained from each article: first
author, year of publication, study population, number of
patients, patient characteristics including: age, gender, etc.
and odd ratio with 95% confidence interval (Table 1).
Results
The initial search generated 1354 articles, five of which
were identified as being strongly relevant following
Excluded based on
duplicate, title and 
abstract: 1,304
Relevant articles in in the primary
search : 1,354
Retained based on title 
and abstract : 50
Excluded based on 
full text study : 43
Full text articles eligible 
for inclusion : 7
Studies included in 
systematic review :  5
Fig. 1 PRISMA flow diagram: summary of search strategy in
this study
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review of title and abstract. The detailed selection
process is presented in Fig. 1 and a detailed review of co-
herent data is collected in Table 1. The included articles
were studies about the association between PLA2 poly-
morphism and DVT, PE, or VTE.
The patient populations of the selected papers were
from various nationalities.
All patients contributing in these studies were diagnosed
with venous thrombotic events with or without PE. The
patient populations ranged between 23 and 121 cases.
In all evaluated studies, PLA2 polymorphism was eval-
uated via restricted fragment length polymorphism
(RFLP) PCR.
In all studies, DVT was diagnosed and confirmed using
standard methods including ultrasonography, Doppler
ultrasonography, D-dimer, and clinical symptoms. Various
techniques were also used for PE diagnosis such as clinical
presentation, chest X-ray, ventilation perfusion lung scan,
electrocardiogram, determination of blood gases, and D-
dimer test. PLA2 polymorphism prevalence was reported
13–42.9% in patients (mean = 27.95%).
The median age was within the range of 34–61 years.
One of five papers compared age between cases with
thrombosis risk concomitant with PLA2 allele and with-
out it [15].
PLA2 polymorphism was associated with VTE in one
study [14], but not in another one [15] (Table 1). One of
the studies found no correlation between PLA2 poly-
morphism and thrombotic events in patients with age 60
years or older (P = 0.5) [15]. In two of the selected stud-
ies, the correlation between PE and PLA2 polymorphism
was investigated; one of them showed no association
[19], whereas the other one reported the correlation (P =
0.003) [20]. In the latter, the prevalence of PLA2 in pa-
tients with recurrent PE events was 37% (OR 3.52, CI
1.21–10.3) and one patient was homozygous genotype
for this polymorphism.
The association between PLA2 polymorphism and
DVT was reported in one of the articles. According to
the findings, the frequency of PLA2 polymorphism was
significantly higher in DVT, compared to control group
(P < 0.001) [19]; however, no significant difference was
found in the frequency of this polymorphism between
PE/DVT or PE patients and control group.
One of the studies investigated the association be-
tween PLA2 polymorphism and thrombotic events in
Behcet's disease [21]. In this study, the frequency of
PLA2 polymorphism was compared between the Behcet
patients with DVT and control group. No significant dif-
ference was observed between Behcet’s disease (BD) and
control in the frequency of PLA2 polymorphism, but
was found between these patients with DVT and control
(OR 2, CI 1.1–3.7) (21). Carriage rate was also signifi-
cantly higher in BD patients with DVT than control (P =
0.044, OR 2.2, CI 1.1–4.5).
The association between recurrent events and PLA2
polymorphism was found in another study [14]. Carriage
of this polymorphism had more recurrent VTE events
than other patients.
In one of the studies, the effect of aspirin consumption
was studied on the association between PLA2 poly-
morphism and thrombosis. The exclusion of these pa-
tients from the cohort had no effect on final output [15].
The prognostic value of PLA2 polymorphism and its
correlation with DVT, PE, or VTE has not been thor-
oughly evaluated. Nevertheless, the predictive value of
this genetic marker has been mostly evaluated in cases
with stroke or coronary thrombosis [12, 13, 22].
In 1996, Weiss et al. reported a relationship between
the PLA2 allele and elevated risk of premature coronary
thrombosis [12]. Some years later, in 1999, Feng et al.
suggested that PLA2 allotype in GP IIb/IIIa could be a
risk factor in patients with VTE. The PLA1/PLA2 poly-
morphism is characterized by increased affinity of the
GP IIb/IIIa platelet receptor for fibrinogen and enhances
platelet aggregation as a baseline for thrombosis [22].
Despite this, in 2008, Ivanov et al. declared no associ-
ation between PLA2 polymorphism and risk of VTE, but
Table 1 Extracted data from included studies investigating the correlation between PLA2 polymorphism and VTE
Author Country Patients number Median age OR 95% CI Type of disease Frequency of PLA2 polymorphism (%) p value
Ridker et al 1997 USA 121 61 1.07 0.7–1.6 VTE 28.1 0.5
Ivanov et al 2008 Bulgaria 51 48.7/45.47 3.27 1.36–7.93 PE 35.3 0.003





Iran 72 52.12 3.4 1.8–6.44 VTE 27.8 < 0.001
Karimi et al 2015 Iran 23 NR 1.33 0.37–4.71 PE/DVT 13 NS
37 1.37 0.5–3.82 PE 13.5
35 6.65 3.09-14.30 DVT 42.9 < 0.001
NR data not reported, NS not significant, N number, OR odds ratio, CI confidence interval, VTE venous thromboembolism, PE pulmonary embolism, DVT deep
vein thrombosis
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it could be a potential risk factor for developing PE [20].
Their data showed comparable OR to other known
thrombophilic mutations, FVL and FII G20210A. They
reported that dual carriers of FVL/PLA2 along with early
manifestation and unusual position of thrombosis had
recurrent PE.
In another study in 2012, Pourgheysari et al. reported
that PLA2 polymorphism is highly associated with VTE
[14].This was the only inherited thrombophilic risk factor
that was correlated with VTE among investigated poly-
morphisms, FVL, FIIG20210A and HTHFR. The PLA2
polymorphism also played a role in recurrent events in
spite of the other polymorphisms. This finding demon-
strated the importance of population-based studies.
According to the results of this systematic review, PLA2
polymorphism increased the thrombotic tendency, but no
consistency was found between different studies. While
Ivanove et al. demonstrated the association of the poly-
morphism with PE, Karimi et al. found no relationship. In-
stead, they found the association with DVT [20, 19].
A main limitation of the present review was the lack of
enough comparable reports and paucity of research in this
study. Due to the low number of publications, the study is
not adequately powered to identify the importance of this
polymorphism. Because of the limited accessibility of data,
it was not possible to perform univariate or multivariate
analyses of individual markers in all studies.
Conclusion
It was concluded that PLA2 polymorphism is a risk factor
for VTE in some patients. Whether this marker can be
used as an important factor in the diagnosis and treatment
of patients with DVT or PE needs more investigation. The
predictive value of the polymorphism is not clear from the
existing publications. As the data were little and somehow
incompatible, it cannot be concluded that PLA2 poly-
morphism is associated with an increased risk of VTE and
this hypothesis needs more trainings.
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